Mitomycin Exhibits Durable Responses in Recurrent, Low-Grade NMIBC
Adverse reactions in the phase 3 ENVISION trial were largely mild to moderate in severity, and serious reactions occurred in 12% of those with NMIBC.
Previous Post
Guselkumab is safe and effective in patients with moderate-to-severe Crohn’s disease
Next Post
New Pirtobrutinib Data Compare Favorably With Ibrutinib in CLL/SLL
📢
Advertisement
300x250 Banner
Recent Content
COPD Biologics: Early Treatment Insights
Pulmonology • 2 hours ago
Antihypertensive Medication Guidelines
Cardiology • 4 hours ago
Juvenile Arthritis Care Transition
Rheumatology • 6 hours ago